OxFORD Asset Management LLP decreased its position in shares of Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) by 44.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,597 shares of the biotechnology company’s stock after selling 22,572 shares during the quarter. OxFORD Asset Management LLP owned approximately 0.15% of Novelion Therapeutics worth $201,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in NVLN. State of Wisconsin Investment Board acquired a new position in shares of Novelion Therapeutics during the 2nd quarter valued at about $102,000. Franklin Resources Inc. boosted its position in shares of Novelion Therapeutics by 4.2% during the 2nd quarter. Franklin Resources Inc. now owns 12,798 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 511 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Novelion Therapeutics by 8,096.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,179 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 14,006 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Novelion Therapeutics during the 2nd quarter valued at about $146,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Novelion Therapeutics during the 2nd quarter valued at about $149,000. 75.55% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently weighed in on NVLN. ValuEngine cut shares of Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 12th. Royal Bank of Canada reissued a “hold” rating and set a $9.00 price target on shares of Novelion Therapeutics in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research lowered shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th.

Shares of Novelion Therapeutics Inc (NASDAQ:NVLN) opened at $3.12 on Monday. The stock has a market cap of $58.19, a PE ratio of -0.45 and a beta of 0.56. Novelion Therapeutics Inc has a fifty-two week low of $3.08 and a fifty-two week high of $12.12. The company has a debt-to-equity ratio of 6.53, a current ratio of 1.45 and a quick ratio of 1.28.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/01/01/oxford-asset-management-llp-sells-22572-shares-of-novelion-therapeutics-inc-nvln.html.

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Want to see what other hedge funds are holding NVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT).

Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.